

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA Naltrexone–bupropion for managing overweight and obesity [ID757]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

<p>The committee recognised the following equality and equity issues during the appraisal discussion but none have impact on the equality or availability of naltrexone-bupropion:</p>
--

- |   |
|---|
| <ul style="list-style-type: none"><li>• There is a disparity between guidance and availability of weight loss services across England.</li><li>• Orlistat is the only treatment currently available to overweight and obese people and is misprescribed in many local jurisdictions</li></ul> |
|---|

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

<p>There were concerns raised that there is a disparity between guidance and the availability of tier 4 (bariatric surgery) services available to those eligible in many jurisdictions across the country. This was out of the remit of the committee's considerations.</p>
---

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other quality issues raise by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No adverse impact on people with disability.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No recommendations the committee need to make.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes. Section 3.1 and 3.2.

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 27 April 2017

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of naltrexone–bupropion for managing overweight and obesity [ID757]

Issue date: December 2017

## Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

The company claimed there could be a discrimination on the basis of age if the inherent underestimations in the model were not considered by the committee. The model did not capture all the possible obesity-related events that may occur. NICE regularly considers technologies for older people in incurable illnesses where the long-term benefits are captured by extrapolating the data. Preventative technologies are used in younger populations and so all the benefits may not be captured in the same way.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations have not changed after consultation. The committee concluded there was no discrimination on the basis of age because age is not used as a defining characteristic for people to have, or not have, treatment and therefore does not affect the current recommendations.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations have not changed after consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified

in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations have not changed after consultation.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes in section 3.18 of the final appraisal determination.

**Approved by Associate Director (name):** .....Janet Robertson...

**Date:** 11/12/2017